Companies Dominating the Wilson Disease Drugs Landscape
- Merck & Co., Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bausch Health Companies Inc.
- Alexion Pharmaceuticals, Inc.
- Nobelpharma Co., Ltd.
- Kodmon Holdings, Inc.
- Teva Pharmaceutical Industries Ltd.
- Tsumura & Co.
- VHB Medi Sciences Limited
- Pfizer Inc.
- Lupin Limited
- Vivet Therapeutics
- NAVINTA LLC
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of wilson disease drugs is estimated at USD 697.71 million.
The wilson disease drugs market size was over USD 652.08 million in 2024 and is anticipated to cross USD 1.12 billion by 2037, witnessing more than 4.3% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of Wilson’s disease in the young population and increasing health spending across the globe will boost the market growth.
North America industry is poised to dominate majority revenue share of 30% by 2037, propelled by presence of leading market players in the region which manufacture and distribute Wilson disease drugs.
The major players in the market are Merck & Co., Inc., Bausch Health Companies Inc., Alexion Pharmaceuticals, Inc., Nobelpharma Co., Ltd., Kodmon Holdings, Inc., Teva Pharmaceutical Industries Ltd., Tsumura & Co., VHB Medi Sciences Limited, Pfizer Inc., Lupin Limited, Vivet Therapeutics, NAVINTA LLC
